What is PredictImmune?
Founded in 2017 and headquartered in Cambridge, England, PredictImmune operates at the intersection of biotechnology and clinical diagnostics. The company specializes in the development of prognostic tests designed to manage immune-mediated diseases, a critical area of unmet medical need. By providing clinicians with actionable data, PredictImmune enables personalized treatment pathways that improve patient quality of life while optimizing healthcare resource allocation. Its market position is defined by its focus on high-value diagnostic tools that address the complexities of chronic inflammatory conditions, positioning the firm as a key player in the evolving landscape of precision health and molecular diagnostics.
How much funding has PredictImmune raised?
PredictImmune has raised a total of $16.6M across 2 funding rounds:
Series A
$5.9M
Series B
$10.7M
Series A (2018): $5.9M with participation from The Wellcome Trust
Series B (2019): $10.7M led by BFG and Parkwalk
Key Investors in PredictImmune
The Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere through grants, partnerships and advocacy.
Parkwalk
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
BFG
An institutional investor participating in the strategic financing round to support the growth and commercialization efforts of the company.
What's next for PredictImmune?
Looking ahead, PredictImmune is poised to leverage its recent capital injection to drive commercial adoption and further clinical validation of its diagnostic suite. The company's strategic roadmap likely includes expanding its operational infrastructure to support broader market access and deepening its research pipeline to address additional immune-mediated indications. As the firm scales, the focus will remain on establishing long-term partnerships with healthcare providers and pharmaceutical entities to integrate its prognostic solutions into standard clinical practice. This phase of development is critical for cementing the company's status as a leader in the diagnostic technology space, ensuring that its innovative research translates into tangible, scalable clinical impact.
See full PredictImmune company page
